• Shingo Iwamoto appointed country head for Sandoz in Japan
  • Shingo Iwamoto will also oversee Japanese business of Aspen Global Incorporated (AGI), successfully acquired by Sandoz on February 1 this year
  • Japan, world’s third largest generics and off-patent market, is central to Sandoz global strategy

Tokyo, March 25, 2020 Sandoz announced today that Shingo Iwamoto, currently President and representative director of Aspen Japan, has been appointed Country Head for Sandoz in Japan with effect from April 1, 2020. He will …

  • Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones
     
  • In addition to meeting both co-primary efficacy endpoints, nine of 22 patients in the completed pivotal STR1VE-US study demonstrated the “ability to thrive,” a stringent composite endpoint remarkable compared to untreated children with SMA Type 1
     
  • Ongoing START long-term follow-up study (cohort 2) demonstrated sustained durability of Zolgensma, …
  • SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12, twice the clinically meaningful threshold, as measured by a validated, widely utilized and highly accepted scale developed specifically for older patients with SMA
     
  • Nearly all patients (92%) in this cohort achieved a clinically meaningful ≥3-point increase during the study period, demonstrating a consistent response following gene therapy
      …
  • Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.
     
  • Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
     
  • Commitment builds on recently announced USD 20 million Novartis COVID-19 Response Fund, drug discovery and development collaborations and essential medicines price stability
     
  • Novartis …
  • Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.
  • Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
  • Commitment builds on recently announced USD 20 million Novartis COVID-19 Response Fund, drug discovery and development collaborations and essential medicines price stability
  • Novartis encourages industry, …
  • Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at diagnosis
     
  • Zolgensma has demonstrated significant and clinically meaningful therapeutic benefit in symptomatic and pre-symptomatic SMA, including prolonged event-free survival and achievement of motor milestones unseen in natural history of the disease
     
  • Designated as an intractable disease in Japan, SMA is the leading …
  • Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH)1,2 

  • Inclisiran reduced LDL-C at 17 months by 52% in patients with ASCVD (ORION-10), 50% for ASCVD and ASCVD risk equivalents (ORION-11) and by 50% in HeFH patients (ORION-9); all of whom had elevated LDL-C levels despite maximally tolerated lipid-lowering therapy1,2

  • Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak
     
  • Novartis to join collaborative R&D efforts with the Bill & Melinda Gates Foundation, Wellcome, and Mastercard -supported COVID-19 Therapeutics Accelerator and a partnership with the Innovative Medicines Initiative (IMI)
     
  • Commitments build on Sandoz pledge to maintain price stability of essential medicines and strong support of patients and healthcare systems
  • Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak
     
  • Novartis to join collaborative R&D efforts with the Bill & Melinda Gates Foundation, Wellcome, and Mastercard -supported COVID-19 Therapeutics Accelerator and a partnership with the Innovative Medicines Initiative (IMI)
     
  • Commitments build on Sandoz pledge to maintain price stability of essential medicines and strong support of patients and healthcare systems

Although artificial intelligence has been around for decades, recent developments in the realm of deep learning have enabled data scientists to make surprising leaps. Unlike conventional machine learning algorithms, which learn from the data input, deep learning applies algorithms in layers to create an “artificial neural network” that can learn and make intelligent decisions on its own.

One of the leaders in this emerging field, DeepMind, a unit of the company Alphabet, beat a human player in the highly complex Chinese board game “Go” around three years ago and, using a similar …